CAS: 12126-59-9; Premarin

该化合物是主要来自孕妇尿液的雌激素混合物,这些化合物用于激素替代疗法,特别是用于缓解更年期症状和防止绝经后妇女骨质疏松,同卵激素的主要特征包括它们能够与雌激素受体结合,从而对各种组织,包括生殖系统,骨骼和心血管系统产生影响,通常通过口服或注射方式进行,能够影响月经周期,促进第二性特征的发展,并支持总体生殖健康.众所周知,同卵激素具有致癌性,包括主要在肝脏和尿液排泄过程中的代谢性.尽管这些种的主要特征是,但使用与潜在的副作用和风险有关,例如血栓性事件和某些癌症,需要保健提供者仔细考虑和监测.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-9290699-B2
    优先权日:2012-06-18
    标 题 :Process for synthesizing hydrocarbons from synthesis gas with control of the temperature of the external loop
    发明人:HERAUD JEAN PHILIPPE; VIGUIE JEAN CHRISTOPHE; BOUCHER SEBASTIEN; DELLA TORRE CHIARA; MIGNONE ELSA
    权利人:IFP Energies Nouvelles; ENI SPA
    摘要:The present invention concerns a process for the synthesis of hydrocarbons from a feed comprising synthesis gas, in which a solid catalyst comprising cobalt is used in a three-phase reaction section operated such that said catalyst is maintained in suspension in a liquid phase by movement of a gas phase from the bottom to the top of said reaction section, said process comprising an external loop for separating waxes, characterized in that:n 1) the theoretical ratio P H2O :P H2 in the external loop for separating waxes is determined using the following calculation:n nP H2O :P H2 theoretical= Cv /( R 1− Rft×Cv )n where Cv=(CO inlet −CO degas )/CO inlet R1=H 2 inlet /CO inlet Rft=(H 2 inlet −H 2 degas )/(CO inlet −CO degas ) n 2) if the theoretical ratio P H2O :P H2 determined in step 1) has a value of R threshold or higher, the temperature in the degassing means for the external loop for separating waxes is reduced, 3) steps 1) to 2) are repeated until the theoretical ratio P H2O :P H2 has a value strictly less than R threshold , where R threshold is in the range 0.1 to 1.1.

    专利号:US-10457640-B2
    优先权日:2016-10-19
    标 题:Synthesis of inhibitors of EZH2
    发明人:VASWANI RISHI G; HEWITT MICHAEL CHARLES
    权利人:CONSTELLATION PHARMACEUTICALS INC
    摘要:Provided herein are synthetic methods for the preparation of EZH2 inhibitors.

    专利号:US-9365532-B1
    优先权日:2011-02-14
    标题:Synthesis, composition and use of novel therapeutic and cosmetic Schiff base products formed by reaction of a carbonyl containing moeity with a transimination nucleophilic catalyst and the use of transimination nucleophilic catalysts to increase the rate at which carbonyl containing therapeutic and cosmetic actives form Schiff base products with biological amines
    发明人:ISAACMAN STEVEN
    权利人:ISAACMAN STEVEN; NANOMETICS LLC
    摘要:The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base product is highly reactive towards transimination with a biological amine. The catalyst and carbonyl-containing moiety can be molecular or polymeric, and the resultant chemical and physical properties of the Schiff base products can be engineered by appropriate selection of said catalyst. The present invention also relates to the synthesis, composition and use of novel moieties that are used as actives in sunless tanning preparations. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate at which a carbonyl-containing moiety reacts with a biological amine. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate and efficacy of commercial sunless tanning preparations. Improvements on stability and efficacy of said preparations are disclosed. While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.

    专利号:US-2019031650-A1
    优先权日:2016-01-29
    标 题 :Dna alkylation and cross-linking agents as compounds and payloads for targeted therapies
    发明人:HERZON SETH; HEALY ALAN; CRAWFORD JASON; VIZCAINO MARIA; NIKOLAYEVSKIY HERMAN
    权利人:UNIV YALE
    摘要:The present invention is directed to compounds related to precolibactin pharmaceutical compositions based upon these compounds and methods of synthesis which are employed to provide intermediates and final compounds, which are principally alkylating agents and anticancer compounds. The chemical synthetic approach disclosed facilitates the synthesis of numerous precolibactin analogs which can be used in the treatment of cancer.

    专利号:US-2003158432-A1
    优先权日:2002-01-08
    标 题:Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex

    专利号:US-2019233375-A1
    优先权日:2016-10-19
    标题:Synthesis of inhibitors of ezh2
    盐城信谊医药化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.xypharm.com
    电话: 0515-84383317 13912580215👤
    📞盐城信谊医药化工有限公司 ⚠️参考联系方式

    销售电话:0515-84383317 13912580215
    邮箱:xypharm@xypharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    江苏 滨海县 江苏滨海县头罾沿海化工园区
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol. 2014 May;7(3):281-91. doi: 10.1586/17512433.2014.893819. Epub 2014 Mar 3. Review. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014 Feb;99(2):E189-98. doi: 10.1210/jc.2013-1707. Epub 2014 Jan 17. doi: 10.1208/s12248-015-9805-x. Epub 2015 Aug 5.
    4: Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther. 2014 Apr 28;56(1441):33-4. doi: 10.1517/14740338.2013.824965. Epub 2013 Aug 7. Review. doi: 10.1331/JAPhA.2014.14517. doi: 10.1152/ajpendo.00653.2013. Epub 2014 Jun 17. doi: 10.3109/13697137.2013.810437. Epub 2013 Jun 27. Review. doi: 10.1358/dot.2015.51.2.2281023. Review. doi: 10.1177/2053369115599090. Epub 2015 Aug 19. Review. doi: 10.1089/jwh.2013.4392. Epub 2013 Nov 9. doi: 10.1097/GME.0000000000000174. doi: 10.1016/j.jsbmb.2013.10.011. Epub 2013 Oct 28. Review. doi: 10.1097/AOG.0b013e31823c0145. doi: 10.3109/13697137.2012.696289. Epub 2012 Aug 1. Review. doi: 10.3109/13697137.2016.1146248. Epub 2016 Mar 3. doi: 10.1097/GME.0000000000000541. doi: 10.1002/etc.3447. Epub 2016 Jun 28. doi: 10.1016/j.watres.2014.03.074. Epub 2014 Apr 13.

    合成参考文献


    摘要:American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 3127
    摘要:O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006., p. 421
    摘要:
    摘要:Lewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 3050
    摘要:Physicians Desk Reference 64th ed. Montvale, NJ: PDR Network, LLC, p. 3775 (2010)
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知